DOCSLIB.ORG

HAREL WEINSTEIN Nationality

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HAREL WEINSTEIN Nationality H. Weinstein, CV Revised - 5/2015 Page 1 of 25 Name: HAREL WEINSTEIN Nationality: USA Office Address: Weill Medical College of Cornell University Tel.# 212-746-6358 Department of Physiology and Biophysics, Box 75 E-mail: [email protected] 1300 York Avenue, Room E-509 Fax # 212-746-8690 New York, NY 10021 Home Address: 151 West 86th Street, APT 3C New York, NY 10024-3401 Education: Technion-Israel Institute of Technology 1966, B.Sc. (Chemistry), Haifa, Israel Graduate School of the Technion-IIT 1968, M.Sc. (Quantum Chemistry) Haifa, Israel Graduate School of the Technion-IIT 1971, D.Sc. (Theoret. Phys. Chem.) Mount Sinai School of Medicine Medical Curriculum Postdoctoral Training: 1973-1974 Associate Research Scientist, Chemistry, The Johns Hopkins University (with Robert G. Parr) Positions and Appointments: 1968-1971 Senior Research Assistant, Chemistry, Technion, IIT 1971-1973 Lecturer, Chemistry, Technion, IIT 2-4/74, 3-5/75 Visiting Scientist, Genetics, Stanford University School of Medicine 1974-1976 Assistant Professor of Pharmacology, Mount Sinai School of Medicine 1976-1979 Associate Professor of Pharmacology, Mount Sinai School of Medicine 1979-2002 Professor of Pharmacology, Mount Sinai School of Medicine 1985-2002 Professor and Chairman, Physiology and Biophysics, Mount Sinai School of Medicine 1998-2002 Dr. Harold and Golden Lamport Professor of Physiology and Biophysics, Mount Sinai School of Medicine 1999-2002 Director, Institute for Computational Biomedicine, Mount Sinai School of Medicine 2002-present Maxwell M. Upson Professor and Chairman, Physiology and Biophysics, Weill Cornell Medical College, Cornell University 2002-present Chair, Graduate Program in Physiology, Biophysics and Systems Biology, Weill Graduate School of Medical Sciences, Weill Cornell Medical College, Cornell University 2002-present Director, Institute for Computational Biomedicine, Weill Cornell Medical College, Cornell University 2002-present Tri-Institutional Professor: Rockefeller University, Sloan Kettering Institute, Cornell University 1 H. Weinstein, CV Revised - 5/2015 Page 2 of 25 Scientific and Medical Societies: American Society for Pharmacology and Experimental Therapeutics; American Physiological Society; American Chemical Society; Biophysical Society; New York Academy of Sciences; The Harvey Society; International Society for Quantum Biology and Pharmacology; American Association for the Advancement of Science; Sigma Xi. International Society for Computational Biology Honors and Awards: 1978-82 Irma T. Hirschl Trust Career Scientist Award 1979-84, 1984-89 ADAMHA-NIDA Research Scientist Development Award (K02) 1990-2001 (compet. renew 2002-2007) NIH-NIDA Senior Research Scientist Award (K05) 1982-84/1985-87 Vice President / President - International Society of Quantum Biology 1988 Award for Outstanding Contributions in Research, Intl. Soc. Quantum Biol. 1988 Parke-Davis Distinguished Lecture, Univ. of Michigan 1989/1990 Outstanding Achievement, Life and Health Sciences, IBM Supercomputing Competition 1989-1992 & 1993 Councillor & President, Assoc. Chairmen Depts. Physiology (ACDP) 1992-1993 Chair, Biophysics Section, New York Academy of Sciences 1993-2002 Science Advisory Committee, The NY Academy of Medicine 1998 Named Harold and Golden Lamport Professor of Physiology and Biophysics, Mount Sinai School of Medicine 1998 Elected: Member, Council of the Biophysical Society (1998-2002) 2002 Named: Maxwell M. Upson Professor of Physiology and Biophysics, Weill Medical College of Cornell University 2003 Council, The Harvey Society (2003-2006) 2005 President’s Lecturer, The College on Problems of Drug Dependence 2005 Perspectives Lecture, Molecular Biophysics, 5th Congress Intl Soc Theo Chemical Physics 2006 Distinguished Lecturer, 34th Leermakers Symposium, Wesleyan University. 2006 Elected, President-Elect, The Biophysical Society: President -2008, Past President 2009 2006 Elected, Board of Directors, International Society for Computational Biology 2010 Elected, Board of Directors, Winifred Masterson Burke Medical Research Institute, NY 2010 Elected, Member and ISCB representative on the Research Information Technology Subcommittee of FASEB Science Policy Committee 2011 New and Notable Lecture, 55th Biophysical Society Meeting 2012 Keynote Lecture, 19th EuroQSAR conference on Knowledge Enabled Ligand Design conference in Vienna, Austria. 2013 Invited Plenary Lecture, 59th Benzon Symposium on Membrane proteins: Structure, Function, and Dynamics – Copenhagen, DK 2014 Drs. Gabor and Harriette Kaley Endowed Lecturer, New York Medical College, Valhalla, NY. Other Academic Activities and Experience: 1979-1983 Member, Drug Abuse Biomedical Research Review Committee (Study Section), National Institute on Drug Abuse (NIDA) 1979-1981 Consultant, Merck Sharp and Dohme Laboratories, USA. 1981 Consultant, Drug Science Foundation, Medical College of South Carolina 1986 Consultant, The Upjohn Company, Kalamazoo, Mich. 1985-1986 Member, PROPHET Computer Resource Advisory Panel, NIH-DRR 1988 Member, Supercomputer Evaluation Panel, Office of the Director-NIH. 1975,1979,1983,1992 Member of Technical Review Panels for NIDA-NIH 2 H. Weinstein, CV Revised - 5/2015 Page 3 of 25 1977-1995 Editorial and Advisory Board of MOLECULAR PHARMACOLOGY 1986-1993 Editorial Board of ENZYME 1989-1991 Editor–in–Chief (with G. Naray-Szabo) of REPORTS IN MOL. THEORY 1990-2000 Editorial Board of MOLECULAR ENGINEERING (Coordinating Editor) 1991-present Editorial Board of ADVANCES IN QUANTUM CHEMISTRY 1992-2001 Editorial Board of INTL. JOURNAL OF QUANTUM CHEMISTRY 1991 Consultant, Abbott Laboratories, Chicago, Ill. 1991, 1993 Consultant, Neurogenetic Corp. (Synaptic), Paramus, NJ. 1992 Consultant, Pfizer, Inc. Central Research, CT. 1992-1993 Consultant, Burrows-Wellcome, NC. 1993-2003 Science Advisory Board, TELIK, Inc. (Terrapin Technol., Inc. ), South SF 1999-2004 Science Advisory Board, NovaSite Pharmaceuticals, Inc. San Diego, CA. 2001-2008 Science Advisory Bd., Predix Pharmaceuticals (BioIT), Tel Aviv, Israel. 1998 -2004 Consultant,UCB (CytoMed) - Cambridge, MA 1982, 1986, 1988...Ad-hoc member, Board of Scientific Advisors, Division of Cancer …2000, 2002 Biochemistry and Diagnosis, NCI-NIH 1986-1994 Member, U.S. Department of Energy, Health and Environmental Research Advisory Committee 1993, 1994 Awards Panel, E.O. Lawrence Awards in Life Sciences, US Dept. Energy 1990-1993 Member, Drug Abuse Biomedical Research Review Committee (Study Section), Biochemistry Research Subcommittee, NIDA-NIH. 1997 Member (Chair Designate), Molecular, Cellular and Chemical Neurobiology Research Subcommittee, NIH-NIDA Initial Review Group (NIDA-IRG) 1998-2001 Member, Molecular, Cellular, Developmental Neurobiology (MDCN-3) Study Section, NIH. 1999-2003 Member, Scientific Advisory Council of CERCA -Center for Research in Applied Computation, Montreal, CANADA 1999-2002 Member and Secretary, Board of Directors, NY Structural Biology Center 1999-present Member, Scientific Advisory Board – Inst. for the Study of Aging, NYC. 2001-2004 Member, Board of Directors, Haddassah Medical Organization. 2001-2007 Member, National Allocations Review Panel, NCSA/NPACI Supercomputer Centers 2001 Member, NIH-NSF Panel on Assessing Bioengineering&Bioinformatics Research Training, Education and Career Development 2001-present Member, Publications Committee, International Society for Computational Biology, 2003-2009 Editorial Board of JOURNAL OF MEDICINAL CHEMISTRY 2004-2008 Member, TechConnect Advisory Committee, Microsoft/CTC 2005, 2006, 2011 Member, NIH Director's Pioneer Award (NDPA) Program Review Panel 2005-2010 Member, Scientific Review Committee, Dulbecco Telethon Institute, Italy 2007-present Member, NIH Study Section: Biophysics of Neuronal Systems (BPNS) 2007-2010 Member, Board of Directors, International Society for Computational Biology 2007-2014 Member, NIH Director's New Innovator Award Program Review Panel 2008-2009 President, The Biophysical Society 2008-present Member, Public Affairs Committee, The Biophysical Society 2010-present Member, Board of Directors, Winifred Masterson Burke Medical Research Institute, Inc. 2010-2012 Chair, NIH Study Section: Biophysics of Neuronal Systems (BPNS) 2014-2018 Member, Executive Committee, Neuropharmacology Div., ASPET 2014- Member, Editorial Review Panel NIH Director's New Innovator Award Active Member - NIH Reviewer Reserve (CSR), review panels for NSF and the Canadian Research Council, The Wellcome Trust, HHMI, HFS. Reviewer for: PNAS, J. AMER. CHEM. SOC., J. PHYS. CHEM., BIOPHYS. J., NATURE, SCIENCE, CELL, 3 H. Weinstein, CV Revised - 5/2015 Page 4 of 25 PROTEIN SCIENCE, J. MED. CHEM., PROT. ENGNG., J. THEORET. BIOL., J. BIOL. CHEM., J. PHARMACOL. EXPTL. THERAP., ENDOCRINOLOGY, COMPUT AIDED MOL. DESIGN, RECEPTORS & CHANNELS, NEUROSCIENCE Letters etc. Teaching Experience 1966-1973 Chemistry Courses: General, Physical, Chemical Bond, Quantum Chemistry 1973 Quantum Mechanical Approaches to Drug-Receptor Interaction Studies (Israel Institute for Biological Research) 1975-1987 Molecular Aspects of Basic Pharmacology and Receptor Theory, In: Basic Pharmacology graduate course in Biological Sciences Program, City University of New York. 1976-1986 Physicochemical Principles of Drug Action, Receptor Theory, Pharmacokinetics, General Anesthetics, Structural Concomitants of Drug Side Effects. In: Systemic Pharmacology, Medical School Course, Mount Sinai School of Medicine 1977-1986 Conference Leader in Neurosciences and in Systemic Pharmacology Courses
Load more

Recommended publications
  • Our Alumni: Where Are They Now?
    Department of Pharmacology and Systems Therapeutics Interdisciplinary Training Program in Drug Abuse Research Annenberg Building, Room 19-84 One Gustave L. Levy Place, Box 1603 New York, NY 10029 Our Alumni: Where Are They Now? The Icahn School of Medicine at Mount Sinai NIDA Training Program has strengthened considerably in recent years. Our trainees have authored or co-authored publications in leading journals, including Science, Neuron, Cell, and Journal of Neuroscience, and have been recruited to academic positions at various institutions. Many of our former fellows have faculty positions and have obtained investigator initiated awards, including those from NIDA: Jennifer Bartz, PhD - Assistant Professor, Department of Psychology, McGill University and Adjunct Assistant Professor, Department of Psychiatry, Icahn School of Medicine at Mount Sinai Marta Filizola, PhD - Associate Professor, Department of Structural and Chemical Biology, Icahn School of Medicine at Mount Sinai Danielle Halpern, PsyD - Assistant Clinical Professor, Department of Psychiatry, Seaver Autism Center, Icahn School of Medicine at Mount Sinai Michelle M. Jacobs, PhD - Assistant Professor, Department of Neurology, Icahn School of Medicine at Mount Sinai Alicia Kaplan, MD - Assistant Professor, Department of Psychiatry, Drexel University Andrew Kolodny, MD - Chief Medical Officer, Phoenix House Mary Kay Lobo, PhD - Assistant Professor, Department of Anatomy and Neurobiology, University of Maryland School of Medicine Susana Neves, PhD - Assistant Professor,
    [Show full text]
  • Opioid Receptors: Structural and Mechanistic Insights Into Pharmacology and Signaling
    European Journal of Pharmacology ∎ (∎∎∎∎) ∎∎∎–∎∎∎ Contents lists available at ScienceDirect European Journal of Pharmacology journal homepage: www.elsevier.com/locate/ejphar Opioid receptors: Structural and mechanistic insights into pharmacology and signaling Yi Shang, Marta Filizola n Icahn School of Medicine at Mount Sinai, Department of Structural and Chemical Biology, One Gustave, L. Levy Place, Box 1677, New York, NY 10029, USA article info abstract Article history: Opioid receptors are important drug targets for pain management, addiction, and mood disorders. Al- Received 25 January 2015 though substantial research on these important subtypes of G protein-coupled receptors has been Received in revised form conducted over the past two decades to discover ligands with higher specificity and diminished side 2 March 2015 effects, currently used opioid therapeutics remain suboptimal. Luckily, recent advances in structural Accepted 11 May 2015 biology of opioid receptors provide unprecedented insights into opioid receptor pharmacology and signaling. We review here a few recent studies that have used the crystal structures of opioid receptors as Keywords: a basis for revealing mechanistic details of signal transduction mediated by these receptors, and for the GPCRs purpose of drug discovery. Opioid binding & 2015 Elsevier B.V. All rights reserved. Receptor Molecular dynamics Allosteric modulators Virtual screening Functional selectivity Dimerization 1. Introduction been devoted over the years to reduce the disadvantages of these drugs while retaining their therapeutic efficacy. In the absence of Opioid receptors belong to the super-family of G-protein cou- high-resolution crystal structures of opioid receptors until 2012, pled receptors (GPCRs), which are by far the most abundant class the majority of these efforts used ligand-based strategies, although of cell-surface receptors, and also the targets of about one-third of some also resorted to rudimentary molecular models of the re- approved/marketed drugs (Vortherms and Roth, 2005).
    [Show full text]
  • Dr. Alan Grossfield Research Interests Research Experience and Education
    Dr. Alan Grossfield Associate Professor [email protected] Dept. of Biochemistry and Biophysics http://membrane.urmc.rochester.edu University of Rochester Medical Center Phone: 585-276-4193 601 Elmwood Ave, Box 712 Fax: 585-275-6007 Rochester, NY 14642 Current as of: 1/15/2021 Research Interests • Molecular simulation and statistical mechanics of biological systems • G protein-coupled receptor structure and function • Aggregation of alpha-synuclein and amyloid formation • Phase separation of lipid membranes • New treatments for opioid-induced respiratory depression and addiction • Developing new tools to perform and analyze molecular simulations Research Experience and Education • Associate Professor, Department of Biochemistry and Biophysics University of Rochester Medical Center March 2014 - present • Assistant Professor, Department of Biochemistry and Biophysics University of Rochester Medical Center October 2007- March 2014 • Research Staff Member, IBM T. J. Watson Research Center Biomolecular Dynamics and Scalable Modeling, Blue Gene Project Group Leader: Dr. Michael Pitman September 2004 – September 2007 Molecular dynamics simulations of rhodopsin • Post-doctoral fellow, Washington University Medical School Department of Biochemistry Adviser: Dr. Jay Ponder May 2000 – August 2004 Ion solvation thermodynamics, polarizable force field thermodynamics • Graduate Student, Johns Hopkins Medical School Department of Biophysics and Biophysical Chemistry Adviser: Dr. Thomas Woolf August 1994 – May 2000 Thesis title: Computer
    [Show full text]
  • Paola Bisignano
    Paola Bisignano Postdoctoral researcher Cardiovascular Research Institute University of California in San Francisco 555 Mission Bay Blvd South, MC 3122 San Francisco, CA 94143 [email protected] EDUCATION 2010 – 2013 PhD, Drug Discovery, Istituto Italiano di Tecnologia and Università degli Studi di Genova, Italy. 2006 – 2008 MSc, Cellular and Molecular Biology, Università degli Studi di Genova, Italy, magna cum laude. 2001 – 2005 BSc, Biological Sciences, Università degli Studi di Genova, Italy, magna cum laude. POSITIONS 2015 – present Postdoctoral research, University of California, San Francisco Advisor: Michael Grabe, Cardiovascular Research Institute, Pharmaceutical Chemistry • structure-based drug design for sodium glucose symporters • homology modelling, molecular dynamics simulation, Markov State Modelling 2014 – 2015 Postdoctoral research, Ichan School of Medicine, Mount Sinai, New York Advisor: Marta Filizola, Structural and Chemical Biology • structure-based and ligand-based drug design for GPCR • virtual screening, chemoinformatics. 2013 Temporary research, Istituto Italiano di Tecnologia, Genova, Italy Advisor: Andrea Cavalli, Drug Discovery and Development • in silico multi-target in Alzheimer’s disease • virtual screening, free energy calculations RESEARCH TRAINING 2012 – 2013 Visiting PhD student, Barcelona Biomedical Research Park, Barcelona, Spain Advisor: Gianni de Fabritiis, Multiscale Laboratory • free energy of protein ligand binding on pharmaceutically relevant targets • molecular dynamics simulation, Markov
    [Show full text]
  • Gpcrmd Uncovers the Dynamics of the 3D-Gpcrome
    bioRxiv preprint doi: https://doi.org/10.1101/839597; this version posted December 17, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. GPCRmd uncovers the dynamics of the 3D-GPCRome 1* 1* 2,3 Ismael Rodríguez-Espigares ,​ Mariona Torrens-Fontanals ,​ Johanna K.S. Tiemann ,​ ​ ​ ​ 1 1 1 David Aranda-García ,​ Juan Manuel Ramírez-Anguita ,​ Tomasz Maciej Stepniewski ,​ ​ ​ ​ 1 4,5 1 1 Nathalie Worp ,​ Alejandro Varela-Rial ,​ Adrián Morales-Pastor ,​ Brian Medel Lacruz ,​ ​ ​ ​ ​ 6 7 8,9 10 Gáspár Pándy-Szekeres ,​ Eduardo Mayol ,​ Toni Giorgino ,​ Jens Carlsson ,​ Xavier ​ ​ ​ ​ 11,12 13 14 7 Deupi ,​ Slawomir Filipek ,​ Marta Filizola ,​ José Carlos Gómez-Tamayo ,​ Angel ​ ​ ​ ​ 7 15 7 15 10 Gonzalez ,​ Hugo Gutierrez-de-Teran ,​ Mireia Jimenez ,​ Willem Jespers ,​ Jon Kapla ,​ ​ ​ ​ ​ ​ 16,17 18 13 18,21 George Khelashvili ,​ Peter Kolb ,​ Dorota Latek ,​ Maria Marti-Solano ,​ Pierre ​ ​ ​ ​ 10 7,22 13 7 Matricon ,​ Minos-Timotheos Matsoukas ,​ Przemyslaw Miszta ,​ Mireia Olivella ,​ ​ ​ ​ ​ 7 14 7 7 Laura Perez-Benito ,​ Davide Provasi ,​ Santiago Ríos ,​ Iván Rodríguez-Torrecillas ,​ ​ ​ ​ ​ 15 13 23 15 Jessica Sallander ,​ Agnieszka Sztyler ,​ Nagarajan Vaidehi ,​ Silvana Vasile ,​ Harel ​ ​ ​ ​ 16,17 24,25 2,3,26 4,5 Weinstein ,​ Ulrich Zachariae ,​ Peter W. Hildebrand ,​ Gianni De Fabritiis ,​ ​ ​ ​ ​ 1 6 7 2,7,11,12,✉ Ferran Sanz ,​ David
    [Show full text]
  • Medical Scientist Training Program
    Medical Scientist Training Program Fall Newsletter November 2018 Meet the First Years! / Summer Highlights Faculty Spotlight Alumni News Backpage Bulletin • Page 3• • Page 4 • • Page 6 • • Page 8 • Margaret H. Baron, MD/PhD A Message from the Director The Mount Sinai MSTP is now comfortably into the fall of its 47th year and its 41st year of NIH funding! Our 12 new students matriculated into the MSTP in early July and immersed themselves immediately into their laboratory rotations and the interactive course Problem Solving in Biomedical Sciences (PSBS), in which they worked collaboratively and brainstormed with a group of enthusiastic faculty to propose studies that address critical biomedical problems. PSBS ended with a stimulating day of rotation presentations by the MD1 students, with MD2 students providing individual feedback (including comments from MTA Directors). They have completed their first course in medical school, STRUCTURES and are now back in graduate school mode for the MSTP core course, Biomedical Sciences for MD/PhDs. They have rapidly integrated into the MSTP and Director, MD/PhD Program we look forward to following their growth and progress over the coming years. Senior Associate Dean for MD/PhD Education Professor of Medicine (Hematology and Medical Oncology) Our 13 most recent graduates are now training in their chosen clinical specialties in top Professor, Cell, Developmental and Regenerative Biology Professor, Oncological Sciences residency programs around the country, while 11 students in their final year of the MSTP have sent out their residency applications and are preparing for interviews. One graduating senior student will pursue a postdoc before applying for residencies.
    [Show full text]
  • A Community Effort to Promote Transparency and Reproducibility in Enhanced Molecular Simulations
    A community effort to promote transparency and reproducibility in enhanced molecular simulations The PLUMED consortium* *To whom correspondence should be addressed: [email protected], [email protected], [email protected], [email protected] List of members of the consortium and authors of the paper Massimiliano Bonomi, Institut Pasteur, CNRS UMR 3528, Paris, France Giovanni Bussi, International School for Advanced Studies, Trieste, Italy Carlo Camilloni, University of Milan, Milan, Italy Gareth Tribello, Queen’s University Belfast, Belfast, UK Pavel Banáš, Palacky University, Olomouc, Czech Republic Alessandro Barducci, Centre de Biochimie Structurale de Montpellier, Montpellier, France Mattia Bernetti, International School for Advanced Studies, Trieste, Italy Peter G. Bolhuis, University of Amsterdam, Amsterdam, The Netherlands Sandro Bottaro, Italian Institute of Technology, Genova, Italy Davide Branduardi, Schrödinger Inc., Cambridge, UK Riccardo Capelli, Forschungszentrum Jülich, Jülich, Germany Paolo Carloni, Forschungszentrum Jülich, Jülich, Germany Michele Ceriotti, Ecole polytechnique fédérale de Lausanne, Lausanne, Switzerland Andrea Cesari, International School for Advanced Studies, Trieste, Italy Haochuan Chen, Nankai University, Tianjin, China Francesco Colizzi, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain Sandip De, BASF, Ludwigshafen, Germany Marco DeLaPierre, Pawsey Supercomputing Centre, Kensington,
    [Show full text]
  • Identification of a Μ-Δ Opioid Receptor Heteromer-Biased Agonist With
    Corrections MEDICAL SCIENCES Correction for “Myc and mTOR converge on a common node Proc Natl Acad Sci USA (110:11988–11993; first published June in protein synthesis control that confers synthetic lethality in 26, 2013; 10.1073/pnas.1310230110). Myc-driven cancers,” by Michael Pourdehnad, Morgan L. Truitt, The authors note that Fig. 5 appeared incorrectly. The cor- Imran N. Siddiqi, Gregory S. Ducker, Kevan M. Shokat, and rected figure and its legend appear below. Davide Ruggero, which appeared in issue 29, July 16, 2013, of AB C Fig. 5. Clinical relevance of mTOR-dependent 4EBP1 phosphorylation in Myc-driven human lymphomas. (A) Analysis of apoptosis in the human Raji Burkitt’s lymphoma cell line upon 4EBP1m expression or MLN0128 treatment for 24 h. Graph represents mean ± SD. (B) Representative H&E, Myc staining, and phospho-4EBP1 staining in human diffuse large B-cell lymphoma (DLBCL). (C) Box and whisker plot of IHC intensity for total 4EBP1 and phospho-4EBP1 from a human DLBCL tissue microarray (TMA) consisting of 77 patients. www.pnas.org/cgi/doi/10.1073/pnas.1317701110 NEUROSCIENCE NEUROSCIENCE Correction for “Identification of a μ-δ opioid receptor heteromer- Correction for “Transient, afferent input-dependent, postnatal biased agonist with antinociceptive activity,” by Ivone Gomes, niche for neural progenitor cells in the cochlear nucleus,” Wakako Fujita, Achla Gupta, Adrian S. Saldanha, Ana Negri, by Stefan Volkenstein, Kazuo Oshima, Saku T. Sinkkonen, Christine E. Pinello, Edward Roberts, Marta Filizola, Peter Hodder, C. Eduardo Corrales, Sam P. Most, Renjie Chai, Taha A. Jan, and Lakshmi A. Devi, which appeared in issue 29, July 16, 2013, Alan G.
    [Show full text]
  • Program Book Cover2
    April 2013 Program Book CAMBRIDGE, MA, APRIL 24-27, 2013 KAPPA THERAPEUTICS conference Table Of Contents PROGRAM COMMITTEE ................................................................................................. 2 SPONSORS ........................................................................................................................... 3 PROGRAM AT A GLANCE ................................................................................................ 4 HOTEL ACCOMMODATIONS/FLOOR PLANS ............................................................ 5 GENERAL INFORMATION ............................................................................................... 7 INSTRUCTIONS FOR PRESENTERS……………………………………………………………..8 KAPPA THERAPEUTICS 2013 PROGRAM ................................................................. 9 WEDNESDAY APRIL 24, 2013 ................................................................................................... 9 THURSDAY APRIL 25, 2013 ........................................................................................................ 9 FRIDAY APRIL 26, 2013 ............................................................................................................ 12 SATURDAY APRIL 27, 2013 ..................................................................................................... 14 POSTER LIST……………………………………………………………………………………..…….17 PROGRAM ABSTRACTS ................................................................................................ 20 Program Committee Charles
    [Show full text]
  • 2020 Research Retreat Department of Pharmacological Sciences Icahn School of Medicine at Mount Sinai
    2020 Research Retreat Department of Pharmacological Sciences Icahn School of Medicine at Mount Sinai September 11, 2020 PROGRAM 9:00 am Welcoming Remarks by Dr. Ming-Ming Zhou 10:21 am Stacy Baker [Reddy] 9:05 am Introduction of DPS Diversity Initiative by the DPS-SPA Team 10:27 am Agata Kurowski [Walsh] Lab Presentations: Session Chair, Daniel Wacker 10:33 am Mustafa Siddiq [Iyengar] 9:15 am Xufen Yu [Jin] 10:39 am Chiara Campana [Sobie] 9:21 am Mariana Lemos Duarte [Devi] 10:45 am Davide Provasi [Filizola] 9:27 am Carolina Rodriguez Tirado [Sosa] 10:51 am Roman Osman 9:33 am Farhana Sakloth [Zachariou] 10:57 am Sherod Haynes [Han] 9:39 am Daniel Stein [Ma’ayan] 11:30 am Meet with Dr. Erik Lium, President of MSIP 9:45 am Michael Capper [Wacker] 12:00 pm Lunch Break 9:51 am Aneel Aggarwal Session Chair, Kathleen Jagodnik 9:57 am Wilnelly Martinez Ortiz [Zhou] 12:30 pm Poster Presentations 10:03 am Michael Lazarus 1:40 pm Keynote: Dr. Chiara Giannarelli 10:09 am William Marsiglia [Dar] 2:25 pm Closing Ceremony 10:15 am Rachel-Ann Garibsingh [Schlessinger] Erik Lium, PhD “Single Cell Immunophenotyping Reveals Novel President, Mount Sinai Innovation Partners Mechanisms of Human Atherosclerosis” Chief Commercial Innovation Officer Chiara Giannarelli, MD, PhD Mount Sinai Health System Assistant Professor, Medicine, Cardiology Dr. Lium is the President of Mount Sinai Innovation Assistant Professor, Genetics and Genomic Sciences Partners (MSIP), the commercialization engine of the Icahn School of Medicine at Mount Sinai Mount Sinai Health System.
    [Show full text]
  • Structure-Based Characterization of Novel TRPV5 Inhibitors
    RESEARCH ARTICLE Structure-based characterization of novel TRPV5 inhibitors Taylor ET Hughes1†, John Smith Del Rosario2†, Abhijeet Kapoor3†, Aysenur Torun Yazici2, Yevgen Yudin2, Edwin C Fluck III1, Marta Filizola3*, Tibor Rohacs2*, Vera Y Moiseenkova-Bell1* 1Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States; 2Department of Pharmacology, Physiology and Neuroscience, New Jersey Medical School, Rutgers University, Newark, United States; 3Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, United States Abstract Transient receptor potential vanilloid 5 (TRPV5) is a highly calcium selective ion channel that acts as the rate-limiting step of calcium reabsorption in the kidney. The lack of potent, specific modulators of TRPV5 has limited the ability to probe the contribution of TRPV5 in disease phenotypes such as hypercalcemia and nephrolithiasis. Here, we performed structure-based virtual screening (SBVS) at a previously identified TRPV5 inhibitor binding site coupled with electrophysiology screening and identified three novel inhibitors of TRPV5, one of which exhibits high affinity, and specificity for TRPV5 over other TRP channels, including its close homologue TRPV6. Cryo-electron microscopy of TRPV5 in the presence of the specific inhibitor and its parent compound revealed novel binding sites for this channel. Structural and functional analysis have *For correspondence: allowed us to suggest a mechanism
    [Show full text]
  • Atomic-Level Characterization of the Methadone-Stabilized Active Conformation of Μ
    Molecular Pharmacology Fast Forward. Published on July 17, 2020 as DOI: 10.1124/mol.119.119339 This article has not been copyedited and formatted. The final version may differ from this version. MOL#119339 Atomic-Level Characterization of the Methadone-Stabilized Active Conformation of µ- Opioid Receptor Abhijeet Kapoor, Davide Provasi, and Marta Filizola Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, Downloaded from NY, USA molpharm.aspetjournals.org at ASPET Journals on September 28, 2021 This work was supported by a National Institutes of Health grant [DA045473] 1 Molecular Pharmacology Fast Forward. Published on July 17, 2020 as DOI: 10.1124/mol.119.119339 This article has not been copyedited and formatted. The final version may differ from this version. MOL#119339 Running title: Methadone-Induced µ-Opioid Receptor Activation Corresponding author: Marta Filizola, Ph.D., Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA; Tel. 212-659-8690; Fax: 212-849-2456; [email protected] Downloaded from Number of text pages: 42 Number of tables: 0 Number of figures: 6 molpharm.aspetjournals.org Number of references: 52 Number of words in the Abstract, Introduction, and Discussion: 183, 592, 1190 at ASPET Journals on September 28, 2021 Abbreviations: CGenFF, CHARMM General Force Field; DOPE, Discrete Optimized Protein Energy; GPCR, G Protein-Coupled Receptor; H8, helix 8; HTMD, high-throughput molecular dynamics;
    [Show full text]